Abstract Library

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4657 Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,

#4563 Clinical case of a young woman with acromegaly, hyperprolactinemia and pituitary tumour with mixed morphology of adenoma and gangliocytoma

Introduction: Acromegaly is a rare disorder that develops due to persistent hypersecretion of somatotropic hormone in adults after closure of the growth plates. In the majority of cases, the cause is a pituitary adenoma.

Conference:

Presenting Author:

Authors: Markova M, Kirova I, Elenkova A, Robeva R, Zacharieva S,

Keywords: acromegaly, hyperprolactinemia, pituitary adenoma, gangliocytoma,

#4556 Optimising the establishment of patient-derived models for neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are clinically and molecularly diverse, with limited understanding of their tumour biology. Efforts to develop patient-derived models have been unsuccessful, highlighting an urgent need for accurate models to support fundamental research.

Conference:

Presenting Author: Hernández Llorens M

Authors: Hernández-Llorens M, Baena-Moreno M, Lamas-Paz A, Sarmentero J, Anton-Pascual B,

Keywords: patient-derived model, organoids, PDXs, Growth factor,

#4542 Results of active observation of pancreatic non-functioning neuroendocrine tumours – Medical registry data

Introduction: Algorithm for stage T1 pancreatic neuroendocrine tumours (PNETs) treatment requires clarification.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A, Petrova A,

Keywords: Neuroendocrine tumour, PNET, pancreatic NET, management, active observation, follow-up, registry, CHEK2, oestrogen,